Inspire Medical Systems (NYSE:INSP) Given New $85.00 Price Target at Mizuho

Inspire Medical Systems (NYSE:INSP) had its price target lowered by Mizuho from $130.00 to $85.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price points to a potential upside of 24.10% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Oppenheimer lowered shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 22nd. Truist Financial decreased their price objective on Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday. Royal Bank Of Canada downgraded Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $175.00 to $90.00 in a report on Tuesday, January 27th. Piper Sandler reduced their target price on Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Wells Fargo & Company set a $70.00 price target on shares of Inspire Medical Systems and gave the company an “equal weight” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $113.94.

Inspire Medical Systems Trading Up 0.5%

NYSE:INSP opened at $68.50 on Thursday. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 6.87 and a beta of 0.74. Inspire Medical Systems has a 1-year low of $64.46 and a 1-year high of $197.75. The business’s fifty day moving average price is $96.03 and its 200 day moving average price is $91.70.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.96. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm had revenue of $269.08 million for the quarter, compared to the consensus estimate of $264.02 million. During the same period in the previous year, the firm posted $1.15 earnings per share. The firm’s revenue was up 12.2% on a year-over-year basis. Equities analysts forecast that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in INSP. Dragoneer Investment Group LLC raised its position in shares of Inspire Medical Systems by 81.4% in the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after buying an additional 1,056,808 shares in the last quarter. Wasatch Advisors LP grew its holdings in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after purchasing an additional 110,288 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Inspire Medical Systems by 68.7% in the third quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after purchasing an additional 528,404 shares during the period. Deerfield Management Company L.P. raised its stake in Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares in the last quarter. Finally, State Street Corp lifted its position in Inspire Medical Systems by 2.3% during the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after purchasing an additional 22,843 shares during the period. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: EPS of $1.65 vs. Street ~$0.70 and revenue of $269.1M (+12% y/y), showing better-than-expected top- and bottom-line execution. Article Title
• Positive Sentiment: Strong full-year metrics and liquidity: 2025 revenue $912M (+14%), operating cash flow $117M, and $175M in share repurchases — supports cash generation and shareholder return capacity. Article Title
• Neutral Sentiment: Management commentary and detail available — full earnings-call transcript and slide deck provide color on Inspire V adoption, payer engagement and margin assumptions for 2026. Useful for modeling scenarios and hearing management’s mitigation plans. Article Title
• Negative Sentiment: Coding & reimbursement risk: Company said recent coding clarification points clinicians to CPT 64582 with a -52 modifier for Inspire V, which may lower physician reimbursement and slow procedure adoption; as a result management narrowed/revised 2026 revenue guidance to $950M–$1.0B (growth ~4%–10%), reflecting meaningful uncertainty. Article Title
• Negative Sentiment: Market reaction and positioning: Shares reportedly slid after the coding/guidance update (coverage noted a roughly 8% drop) and short interest rose materially in January to ~13.6% of float (up ~31%), increasing downside pressure and potential volatility. Article Title

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.